Make the Diagnosis

A 71-year-old White female developed erosions after hip replacement surgery 2 months prior to presentation

A 71-year-old White female developed erosions following hip replacement surgery 2 months prior to presentation. The patient denied any oral, mucosal, or genital lesions. The patient had no systemic symptoms.

What's your diagnosis?

Pemphigus foliaceus

Pemphigus vulgaris

Bullous impetigo

Bullous pemphigoid

Bullous erythema multiforme

The patient had been diagnosed with pemphigus vulgaris (PV) 1 year prior to presentation with erosions on the axilla. Biopsy at that time revealed intraepithelial acantholytic blistering with areas of suprabasilar and subcorneal clefting. Direct immunofluorescence was positive for linear/granular IgG deposition throughout the epithelial cell surfaces, as well as linear/granular C3 deposits of the lower two thirds of the epithelial strata, consistent for pemphigus vulgaris.

PV is a rare autoimmune bullous disease in which antibodies are directed against desmoglein 1 and 3 and less commonly, plakoglobin. There is likely a genetic predisposition. Medications that may induce pemphigus include penicillamine, nifedipine, or captopril.

Clinically, PV presents with flaccid blistering lesions that may be cutaneous and/or mucosal. Bullae can progress to erosions and crusting, which then heal with pigment alteration but not scarring. The most commonly affected sites are the mouth, intertriginous areas, face, and neck. Mucosal lesions can involve the lips, esophagus, conjunctiva, and genitals.

Biopsy for histology and direct immunofluorescence is important in distinguishing between PV and other blistering disorders. Up to 75% of patients with active disease also have a positive indirect immunofluorescence with circulating IgG.

There are numerous reports in the literature of PV occurring in previous surgical scars, and areas of friction or trauma. This so-called Koebner’s phenomenon is seen more commonly in several dermatologic conditions, such as psoriasis, lichen planus, verruca vulgaris, and vitiligo.

Dr. Donna Bilu Martin, Premier Dermatology, MD, Aventura, Fla.

Dr. Donna Bilu Martin

Treatment for PV is generally immunosuppressive. Systemic therapy usually begins with prednisone and then is transitioned to a steroid sparing agent such as mycophenolate mofetil. Other steroid sparing agents include azathioprine, methotrexate, cyclophosphamide, and intravenous immunoglobulin. Secondary infections are possible and should be treated. Topical therapies aimed at reducing pain, especially in mucosal lesions, can be beneficial.

Dr. Bilu Martin is a board-certified dermatologist in private practice at Premier Dermatology, MD, in Aventura, Florida. More diagnostic cases are available at mdedge.com/dermatology. To submit a case for possible publication, send an email to dermnews@mdedge.com.

References

Cerottini JP et al. Eur J Dermatol. 2000 Oct-Nov;10(7):546-7.

Reichert-Penetrat S et al. Eur J Dermatol. 1998 Jan-Feb;8(1):60-2.

Saini P et al. Skinmed. 2020 Aug 1;18(4):252-253.

Recommended Reading

When Does Different Types of Organ Damage From Lupus Occur? Long-Term Study Sheds Light
MDedge Dermatology
Fillers, Hyaluronidase Relieve Orofacial Changes in Patients with Scleroderma
MDedge Dermatology
Patients With Immune-Mediated Inflammatory Diseases, Type 2 Diabetes Reap GLP-1 Receptor Agonist Benefits, Too
MDedge Dermatology
Systemic Sclerosis Without Scleroderma Has Unique Severity, Prognosis
MDedge Dermatology
What’s Causing Raynaud Phenomenon Severity to Rise With High Temperatures?
MDedge Dermatology
Managing Vitiligo: Combination Therapies, New Treatments
MDedge Dermatology
Current Hydroxychloroquine Use in Lupus May Provide Protection Against Cardiovascular Events
MDedge Dermatology
Belimumab Hits Newer Remission, Low Disease Activity Metrics
MDedge Dermatology
Hypnosis May Offer Relief During Sharp Debridement of Skin Ulcers
MDedge Dermatology
Trial Looks at Early Use of Mycophenolate to Reduce Flares, Nephritis
MDedge Dermatology